Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2005-11-04
2009-08-25
Peng, Bo (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S186100, C424S211100, C424S185100, C530S324000, C435S007100
Reexamination Certificate
active
07579004
ABSTRACT:
A preparation of peptides eluted from class II HLA molecules is disclosed. Methods of decreasing measles infections comprising inoculating human patients with a vaccine comprising one or more of the peptides and methods of diagnosing measles infections or immunity comprising analyzing human patients for the presence of one or more of the peptides or antibodies to the peptide(s) are also disclosed.
REFERENCES:
Davidkin, Irja and Valle, Martti. “Vaccine-induced measles virus antibodies after two doses of combined measles, mumps and rubella vaccine: a 12-year follow-up in two cohorts”. Vaccine. 1998, 16: 2052-2057.
Ovysyannikova IG et al “Variation in vaccine response in normal populations”. Pharmacogenomics. Jun. 2004;5(4):417-27.
Caillat-Zueman et al. “Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen”. Kidney Int. Jun. 1998;53(6):1626-30.
Schenke et al. “Binding specificity of a class II-restricted hepatitis B epitope by DR molecules from responder and nonresponder vaccine recipients.”0 Human Immunology. 1998, 59(12):783-93.
Obeid et al “dentification of helper T cell antigenic sites in mice from the haemagglutinin glycoprotein of measles virus” J. Gen Virology, 74:2549-2557, 1993.
Black S, et al., “Efficacy, Safety and Immunogenicity of Heptavalent Pneumococcal Conjugate Vaccine in Children. Northern California Kaiser Permanente Vaccine Study Center Group,” Pediatr. Infect. Dis. J. 19:187-195 (2000).
Booy R, et al., “Vaccine Failures After Primary Immunisation with Haemophilus influenza Type-B Conjugate Vaccine without Booster,” Lancet 349:1197-1202 (1997).
Gerlich W & Bruss V, “Functions of Hepatitis B Virus Proteins and Molecular Targets for Protective Immunity” in Hepatitis B Vaccines in Clinical Practice, 41-82 (Ellis R, ed. 1993).
Jonsdottir I, et al., “Functional Activity of Antibodies Elicited by Octavalent Pneumococcal Polysaccharide Conjugate Vaccines, PncT and PncD,” [Abstract G-90]. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sep. 28 to Oct. 1, 1997.
Jonsdottir I, et al., “Pneumococcal Conjugate Vaccine Induces Protective Immunity in Toddlers,” [Abstract 43]. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sep. 17-20, 2000.
Konishi E & Fujii A, “Dengue Type 2 Virus Subviral Extracellular Particles Produced by a Stably Transfected Mammalian Cell Line and Their Evaluation for a Subunit Vaccine,” Vaccine 20:1058-1067 (2002).
Lottenbach K, et al., “Safety and Immunogenicity of Haemophilus influenzae type B Polysaccharide or Conjugate Vaccines in an Elderly Adult Population,” J. Am. Geriatr. Soc. 52:1883-1887 (2004).
Milch D, “Application of Synthetic Peptide Technology to Experimental HBV Vaccine Design” in Hepatitis B Vaccines in Clinical Practice, 351-381 (Ellis R, ed. 1993).
Nemchinov L, et al., “Development of a Plant-derived Subunit Vaccine Candidate Against Hepatitis C Virus,” Arch. Virol. 145:2557-2573 (2000).
Potter A & Babiuk L, “New Approaches for Antigen Discovery, Production and Delivery: Vaccines for Veterinary and Human Use,” Curr. Drug Targets Infect. Dis. 1:249-262 (2001).
Plotkin S, “Immunologic correlates of protection induced by vaccination,” Pediatr. Infect. Dis. J. 20:63-75 (2001).
Sala F, et al., “Vaccine Antigen Production in Transgenic Plants: Strategies, Gene Constructs and Perspectives,” Vaccine 21:803-808 (2003).
Ovsyannikova I, et al., “Naturally processed measles virus peptide eluted from class II HLA-DRB1 *03 recognized by T lymphocytes from human blood,” Virology 312:495-506 (2003).
Ovsyannikova I, et al., “Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides,” J Virol. 78:42-51 (2004).
Poland G, et al., “Identification of an association between HLA class II alleles and low antibody levels after measles immunization,” Vaccine 20:430-438 (2001).
Johnson Kenneth L.
Muddiman David C.
Ovsyannikova Inna G.
Poland Gregory A.
Mayo Foundation for Medical Education
Peng Bo
Quarles & Brady LLP
LandOfFree
Naturally processed measles virus peptides eluted from class... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naturally processed measles virus peptides eluted from class..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naturally processed measles virus peptides eluted from class... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4127746